Hims & Hers Health Inc. shares fell as the stock hit a 20-day low amid increasing competition from Amazon Pharmacy's launch of Novo Nordisk's Wegovy at competitive prices.
The announcement raises concerns about market share for telehealth providers like Hims, especially as Bank of America downgraded the company's price target and maintained an 'Underperform' rating, citing overly optimistic revenue growth and EBITDA margin estimates for 2026. Despite this, retail sentiment remains positive, with a significant increase in message volume on Stocktwits, indicating some investor confidence in Hims' diversified telehealth platform.
The implications of these developments suggest that Hims may face significant challenges in maintaining its market position, especially with rising short interest and analyst caution regarding its growth potential.
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
7 Hold
3 Sell
Hold
Current: 29.870
Low
29.00
Averages
42.88
High
85.00
Current: 29.870
Low
29.00
Averages
42.88
High
85.00
BofA
Underperform
downgrade
$32 -> $29
2026-01-08
Reason
BofA
Price Target
$32 -> $29
AI Analysis
2026-01-08
downgrade
Underperform
Reason
BofA lowered the firm's price target on Hims & Hers to $29 from $32 and keeps an Underperform rating on the shares. The firm says 2026 consensus estimates for Hims' sales and EBITDA margins are too high. 2026 is a "big investment year" for Hims & Hers and current Street expectations for EBITDA margin expansion "seem overly optimistic," the analyst tells investors in a research note. BofA sees downside risk to 2026 consensus revenue and EBITDA margins and expects negative earnings revisions to take place over the next few months.
Citi
Sell
maintain
$30
2026-01-05
Reason
Citi
Price Target
$30
2026-01-05
maintain
Sell
Reason
Citi believes Novo Nordisk's (NVO) announcement this morning that its Wegovy weight loss pill is now broadly available throughout the U.S. will pressure Hims & Hers (HIMS). Hims was again left off Novo's partners list, which includes CVS Health (CVS) and Costco (COST), LifeMD (LFMD) and GoodRx (GDRX), which likely reflects disagreements between Novo and Hims around Him's compounded semaglutide strategy, the analyst tells investors in a research note. Citi thinks Novo's pill launch will put pressure on Hims & Hers' GLP-1 business in 2026. The firm keeps a Sell rating on the shares with a $30 price target. The stock in premarket trading is up 44c to $33.85.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HIMS
Unlock Now
Barclays
NULL -> Overweight
initiated
$48
2025-12-08
Reason
Barclays
Price Target
$48
2025-12-08
initiated
NULL -> Overweight
Reason
Barclays initiated coverage of Hims & Hers with an Overweight rating and $48 price target.
Barclays
Overweight
initiated
$48
2025-12-08
Reason
Barclays
Price Target
$48
2025-12-08
initiated
Overweight
Reason
Barclays initiated coverage of Hims & Hers with an Overweight rating and $48 price target. With the concerns around the sustainability of the company's compounding strategy now better understood, the firm believes the expectations around the shares have become more reasonable, the analyst tells investors in a research note. The firm added that, looking forward to FY26, it believes the recent addition of other growth drivers help create a more favorable setup for durable growth.
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
